TZDs including pioglitazone and rosiglitazone are used in type 2 diabetes to improve insulin sensitivity, but their use is limited by side effects such as weight gain, edema, and potential cardiovascular risks [116]. The gene discussed is INS; the disease is type 2 diabetes mellitus.